title: Black box warnings in prescription drug labeling: results of a survey of 206 drugs.
authors.affiliation: Hyman, Phelps & McNamara, P.C., Washington, D.C., USA.
authors.forename: J E
authors.initials: JE
authors.lastname: Beach
authors.forename: G A
authors.initials: GA
authors.lastname: Faich
authors.forename: F G
authors.initials: FG
authors.lastname: Bormel
authors.forename: F J
authors.initials: FJ
authors.lastname: Sasinowski
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects; D004346:Drug Information Services / Q000331:legislation & jurisprudence*; D004348:Drug Labeling / Q000145:classification / Q000331:legislation & jurisprudence; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D007880:Legislation, Drug; D016365:Liability, Legal; D014481:United States; D014486:United States Food and Drug Administration; D014635:Valproic Acid / Q000009:adverse effects
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D014635:Valproic Acid